Anti-Hypertensive Drugs - Eastern Asia

Eastern Asia

The Anti-Hypertensive Drugs market in Eastern Asia is expected to witness a substantial increase in revenue, reaching US$3.63bn in 2024.
Furthermore, it is projected to exhibit a steady annual growth rate (CAGR 2024-2028) of 0.27%, ultimately leading to a market volume of US$3.67bn by 2028.
When compared globally, United States is anticipated to generate the highest revenue, amounting to US$12,290.00m in 2024.
In Eastern Asia, Japan leads the market for anti-hypertensive drugs with its advanced research and development in pharmaceuticals.

Key regions: Germany, United States, France, China, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Hypertensive Drugs market in Eastern Asia has been experiencing steady growth in recent years.

Customer preferences: There is a growing demand for Anti-Hypertensive Drugs in Eastern Asia due to the increasing prevalence of hypertension in the region. Customers are seeking effective and affordable drugs to manage their condition, leading to a rise in demand for Anti-Hypertensive Drugs.

Trends in the market: Japan is the largest market for Anti-Hypertensive Drugs in Eastern Asia due to its aging population and high prevalence of hypertension. The market in China is also growing rapidly due to the increasing awareness of hypertension and the growing middle-class population. South Korea and Taiwan are also emerging markets for Anti-Hypertensive Drugs, driven by increasing healthcare expenditure and the rising prevalence of hypertension.

Local special circumstances: In Japan, the government's healthcare system covers a large portion of the population, leading to a high utilization of Anti-Hypertensive Drugs. In China, the government has been promoting the use of generic drugs to reduce healthcare costs, leading to a rise in demand for affordable Anti-Hypertensive Drugs. In South Korea, the government has been implementing policies to encourage the development of the pharmaceutical industry, leading to an increase in local production of Anti-Hypertensive Drugs.

Underlying macroeconomic factors: The aging population in Japan and South Korea is a major driver of the Anti-Hypertensive Drugs market, as hypertension is more prevalent in older individuals. The growing middle-class population in China is also driving the market, as they have more disposable income to spend on healthcare. Additionally, the increasing prevalence of hypertension in the region is a key factor driving the growth of the Anti-Hypertensive Drugs market in Eastern Asia.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.